Navigation Links
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Date:8/19/2007

CRANBURY, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally- delivered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the second quarter of 2007. On a reported basis, calculated in accordance with U.S. generally accepted accounting principals (GAAP), Amicus announced a net loss attributable to common stockholders per share of $1.37 for the three months ended June 30, 2007. On a non-GAAP basis, Amicus reported a net loss attributable to common stockholders per share of $1.17 for the three months ended June 30, 2007. As of June 30, 2007, cash, cash equivalents, and marketable securities totaled $125.7 million.

"We continue to remain very confident in the potential for pharmacological chaperones to treat a range of human genetic diseases, beginning with the lysosomal storage disorders," stated John F. Crowley, President and CEO of Amicus Therapeutics. "We expect to deliver on three significant clinical milestones by the end of 2007: Phase II data for Amigal(TM) for Fabry disease; preliminary Phase II data in the 4-week Plicera(TM) switching study; and, complete Phase I data for AT2220 for Pompe disease."

Quarterly Highlights:

-- Amicus completed its IPO and sold a total of 5,000,000 shares of its

common stock at a public offering price of $15.00 per share. Gross

proceeds to Amicus totaled $75.0 million and after underwriting

discounts and commissions and offering expenses, net proceeds totaled

$68.1 million.

Financial Results

On a reported basis, the net loss attributable to common stockholders for the three months ended June 30, 2007 was $9.7 million as compared to $28.1 million for the same period in 2006. On a Non-GAAP basis, the net loss for the three months ended June 30, 2007 and the three months ended June 30, 2006 was $8.3 million, respectively. The Company recorded no revenues during these periods.

On a Non-GAAP basis, research and development expense for the three months ended June 30, 2007, was $6.4 million, an increase of $0.1 million from $6.3 million for the three months ended June 30, 2006.

On a Non-GAAP basis, general and administrative expense for the three months ended June 30, 2007, was $2.6 million, an increase of $0.4 million from $2.2 million from the three months ended June 30, 2006.

The differences between U.S. GAAP EPS, net loss, research and development and general and administrative and the corresponding non-GAAP amounts are itemized in table 2, and are due to:

-- Pre-tax share-based compensation expense under SFAS 123R of

$1.0 million (or $0.14 per share), primarily related to employee stock

option expense.

-- Pre-tax charge for a deemed dividend of $19.4 million in the second

quarter of 2006.

-- Pre-tax charges for preferred stock accretion.

-- Pre-tax charges for changes in the fair value of warrant liability.

Use of Non-GAAP Financial Measures

Our "non-GAAP net income" and "non-GAAP diluted EPS" financial measures are defined as reported, or GAAP, net income and diluted EPS excluding, for the reasons discussed below, (1) stock option expense and the cumulative effect of an accounting change relating to the initial adoption of SFAS No. 123R and (2) other items. Our management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of the Company from year to year and quarter to quarter. Accordingly, we believe investors' understanding of the Company's financial performance is enhanced as a result of our disclosing these non-GAAP financial measures. Non-GAAP net income and diluted EPS should not be viewed in isolation or as a substitute for reported, or GAAP, net income and diluted EPS.

(1) Stock option expense -- Non-GAAP net income and diluted EPS exclude

the impact of our stock option expense recorded in accordance with

SFAS No. 123R. We believe that excluding the impact of expensing stock

options better reflects the recurring economic characteristics of our

business.

(2) Other items -- Non-GAAP net income and diluted EPS exclude other

unusual or non-recurring items that are evaluated on an individual

basis. Our evaluation of whether to exclude an item for purposes of

determining our non-GAAP financial measures considers both the

quantitative and qualitative aspects of the item, including, among

other things (i) its size and nature, (ii) whether or not it relates

to our ongoing business operations, and (iii) whether or not we expect

it to occur as part of our normal business on a regular basis. Items

excluded for purposes of determining non-GAAP net income and diluted

EPS include deemed dividends, preferred stock accretion, and changes

in the fair value of warrant liability.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The Company is also conducting Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the respective Phase II clinical trials for Amigal(TM) and Plicera(TM), and the Phase I clinical trial for AT2220 may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward- looking statements are qualified in their entirety by this cautionary statement and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD-G

Amicus Therapeutics, Inc.

(a development stage company)

Consolidated Statements of Operations

(Unaudited)

(in thousands, except share and per share amounts)

Period from

February 4,

2002

Three Months Six Months (inception)

Ended June 30, Ended June 30, to June 30,

2006 2007 2006 2007 2007

Operating Expenses:

Research and

development $6,691 $6,783 $12,719 $13,867 $72,671

General and

administrative 2,563 3,189 4,464 6,040 28,832

Impairment of

leasehold

Improvements - - - - 1,030

Depreciation and

amortization 217 312 416 609 2,166

In-process research

and Development - - - - 418

Total operating

expenses 9,471 10,284 17,599 20,516 105,117

Loss from operations (9,471) (10,284) (17,599) (20,516) (105,117)

Other income

(expenses):

Interest income 448 1,060 686 1,753 4,560

Interest expense (74) (86) (125) (179) (1,261)

Change in fair

value of warrant

Liability 471 (86) 127 (149) (454)

Other expense 2 - (1) - (1,181)

Loss before

tax benefit (8,624) (9,396) (16,912) (19,091) (103,453)

Income tax benefit - - - - 695

Net loss (8,624) (9,396) (16,912) (19,091) (102,758)

Deemed dividend (19,424) - (19,424) - (19,424)

Preferred stock

accretion (41) (310) (81) (351) (802)

Net loss

attributable

to common

stockholders $(28,089) $(9,706) $(36,417) $(19,442) $(122,984)

Net loss

attributable

to common

stockholders per

common share --

basic and diluted $(39.04) $(1.37) $(57.78) $(4.80)

Weighted-average

common shares

outstanding --

basic and

diluted 719,556 7,083,748 630,230 4,051,709

See accompanying notes to consolidated financial statements

Amicus Therapeutics, Inc

Statement of Operations Information for 3 months ending June 30, 2007

Change in

Fair

Value of Preferred Stock

Warrant Stock Compen- GAAP as

Non-GAAP Liability Accretion sation Reported

Income Statement

Classifications:

Research and development (6,361) (422) (6,783)

General and

administrative (2,607) (582) (3,189)

Depreciation and

amortization (312) (312)

Interest income 1,060 1,060

Interest expense (86) (86)

Change in fair value

of warrant liability - (86) (86)

Preferred stock accretion - (310) (310)

Summary:

Income (loss) before

income taxes: (8,306) (86) (310) (1,004) (9,706)

Net income (loss): (8,307) (86) (310) (1,004) (9,707)

Net income (loss) per

share - basic

and diluted: (1.17) (0.01) (0.04) (0.14) (1.37)

Weighted average

number of shares

outstanding: 7,083,748 7,083,748

Amicus Therapeutics, Inc

Statement of Operations Information for 3 months ending June 30, 2006

Change in

Fair

Value of Preferred Stock

Warrant Stock Deemed Compen- GAAP as

Non-GAAP Liability Accretion Dividend sation Reported

Income Statement

Classifications:

Research and

development (6,295) (396) (6,691)

General and

administrative (2,202) (361) (2,563)

Depreciation and

amortization (217) (217)

Interest income 448 448

Interest expense (73) (73)

Change in fair value

of warrant liability (0) 471 471

Other 2 2

Deemed dividend - (19,424) (19,424)

Preferred stock

accretion - (41) (41)

Summary:

Income (loss) before

income taxes: (8,338) 471 (41) (19,424) (757) (28,089)

Net income (loss): (8,338) 471 (41) (19,424) (757) (28,089)

Net income (loss)

per share - basic

and diluted: (11.59) 0.65 (0.06) (26.99) (1.05) (39.04)

Weighted average

number of shares

outstanding: 719,556 719,556


'/>"/>
SOURCE Amicus Therapeutics

Copyright©2007 PR Newswire.

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
(Date:2/11/2016)... Feb. 11, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the engagement of Lars E. ... Medical Consultant. Dr. Birgerson will provide strategic medical ... operations team to help ensure timely facilitation of ...
(Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Aytu ... on developing treatments for urological and related conditions, announced ... for the second fiscal quarter of 2016 on Tuesday, ... will review recent accomplishments and provide an overview of ... financial results for the quarter ended December 31, 2015. ...
Breaking Medicine Technology:
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):